Our top pick for
Building a portfolio
Intellia Therapeutics, Inc is a biotechnology business based in the US. Intellia Therapeutics shares (NTLA) are listed on the NASDAQ and all prices are listed in US Dollars. Intellia Therapeutics employs 312 staff and has a trailing 12-month revenue of around USD$58 million.
|52-week range||USD$12.19 - USD$91.9999|
|50-day moving average||USD$65.1499|
|200-day moving average||USD$50.3665|
|Wall St. target price||USD$78.46|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-2.004|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$58 million|
|Gross profit TTM||USD$-92,414,000|
|Return on assets TTM||-16.89%|
|Return on equity TTM||-33.69%|
|Market capitalisation||USD$4.9 billion|
TTM: trailing 12 months
There are currently 8.7 million Intellia Therapeutics shares held short by investors – that's known as Intellia Therapeutics's "short interest". This figure is 8.1% up from 8.1 million last month.
There are a few different ways that this level of interest in shorting Intellia Therapeutics shares can be evaluated.
Intellia Therapeutics's "short interest ratio" (SIR) is the quantity of Intellia Therapeutics shares currently shorted divided by the average quantity of Intellia Therapeutics shares traded daily (recently around 1.6 million). Intellia Therapeutics's SIR currently stands at 5.31. In other words for every 100,000 Intellia Therapeutics shares traded daily on the market, roughly 5310 shares are currently held short.
However Intellia Therapeutics's short interest can also be evaluated against the total number of Intellia Therapeutics shares, or, against the total number of tradable Intellia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Intellia Therapeutics's short interest could be expressed as 0.13% of the outstanding shares (for every 100,000 Intellia Therapeutics shares in existence, roughly 130 shares are currently held short) or 0.1715% of the tradable shares (for every 100,000 tradable Intellia Therapeutics shares, roughly 172 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Intellia Therapeutics.
Find out more about how you can short Intellia Therapeutics stock.
We're not expecting Intellia Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Intellia Therapeutics's shares have ranged in value from as little as $12.19 up to $91.9999. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intellia Therapeutics's is 2.1019. This would suggest that Intellia Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing PNRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing PINC, with 24-hour and historical pricing before you buy.
Steps to owning and managing POAI, with 24-hour and historical pricing before you buy.
Steps to owning and managing PBTS, with 24-hour and historical pricing before you buy.
Steps to owning and managing PTMN, with 24-hour and historical pricing before you buy.
Steps to owning and managing BPOP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PLYA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAGP, with 24-hour and historical pricing before you buy.
Steps to owning and managing PAA, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.